. 2020 Oct 2;24:100822. doi: 10.1016/j.bbrep.2020.100822

Table 1.

The effect of placebo and rosuvastatin treatment on the concentration of the main variables in this study.

Variable	Absolute concentration (mean ± SD)			Difference PB – BL (% mean change)	Difference RS – BL (% mean change)
Variable	Baseline (BL)	Placebo (PB)	Rosuvastatin (RS)	Difference PB – BL (% mean change)	Difference RS – BL (% mean change)
Total cholesterol, mmol/L	6.17 ± 0.47	6.16 ± 0.44	3.81 ± 0.33	−0.01 ± 0.06^a (−0.16)	−2.36 ± 0.14^e (−38.25)
LDL-cholesterol, mmol/L	4.57 ± 0.32	4.56 ± 0.30	2.18 ± 0.19	0.01 ± 0.06^a (0.22)	−2.39 ± 0.13^e (−52.29)
HDL-cholesterol, mmol/L	1.175 ± 0.15	1.186 ± 0.14	1.273 ± 0.16	0.011 ± 0.02^a (0.93)	0.098 ± 0.02^b (8.34)
Apolipoprotein B-100, nmol/L	322.34 ± 46.91	321.90 ± 47.52	175.02 ± 19.15	−0.44 ± 4.54^a (−0.13)	−147.31 ± 31.24^c (−45.70)
Apolipoprotein A-1, nmol/L	37.11 ± 3.44	37.17 ± 3.50	39.17 ± 3.47	0.05 ± 0.28^a (0.13)	2.06 ± 0.14^e (5.55)
Triglycerides, mmol/L	0.93 ± 0.078	0.94 ± 0.063	0.74 ± 0.065	0.01 ± 0.03^a (1.08)	−0.19 ± 0.02^d (−20.43)
Phospholipids, mmol/L	2.45 ± 0.10	2.46 ± 0.12	1.78 ± 0.05	0.01 ± 0.03^a (0.41)	−0.67 ± 0.06^d (−27.35)
Total fatty acids, mmol/L	13.11 ± 0.54	13.17 ± 0.50	9.16 ± 0.28	0.06 ± 0.22^a (−0.46)	−3.95 ± 0.29^e (−30.13)
Total free fatty acids, μmol/L	683.55 ± 29.58	682.06 ± 26.17	537.22 ± 18.36	−1.49 ± 9.54^a (−2.18)	−146.33 ± 18.12^d (−21.41)

^ap > 0.05; ^bp < 0.001; ^cp < 0.0001; ^dp < 0.00001; ^ep < 0.000001.